Promega, CS372004, Antibody Internalization Bioassay

Go from Antibody Binding to Payload Delivery with Confidence
Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs to selectively kill cancer cells. To be effective, ADCs must be internalized and trafficked inside the cell to release their payload and avoid off-target effects. Understanding internalization dynamics early during development helps researchers identify the most promising candidates, avoid costly downstream failures and scale production faster.
Traditional methods to measure antibody internalization face several limitations:
Time-consuming flow cytometry protocols
pH-dependent dye conjugates that alter antibody behavior
Low-throughput fluorescence microscopy assays
What does using the Antibody Internalization Bioassay mean for you?
Bridge the gap between binding affinity and therapeutic cytotoxicity with reproducible internalization measurements.
Screen large panels of antibodies and conjugates for internalization efficiency in days, not weeks.
Remove development risk by eliminating low-internalizing candidates early and avoiding off-target toxicity.